ANNX - Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

2024-06-04 14:07:57 ET

Summary

• Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome.
• Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025.
• If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025.
• ANX007 is another C1q inhibitor in the pipeline, which is being developed to treat patients with geographic atrophy.

Annexon, Inc. ( ANNX ) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its drug, 30 mg/kg ANX005, was able to meet on the primary endpoint of this late-stage study with statistical significance....

For further details see: